Transplantation, MICI et stéatose hépatique : quelques nouveautés en 2023
(2024) Louvain médical — Vol. 143, n° 02-03, p. 183-188 (2024)
Files
2024_Dahlqvist_LM_183-188.pdf
Open Access - Adobe PDF
- 2.99 MB
Details
- Authors
- Abstract
- (en) [Transplantation, chronic inflammatory bowel disease, and hepatic steatosis: highlights in 2023] The year 2023 marked numerous developments and advances in the field of hepato-gastroenterology. The deleterious impact of frailty and sarcopenia on the prognosis of patients with cirrhosis, listed for transplantation, is clear. A care pathway that covers pre-transplant preparation and rehabilitation for up to two years after liver transplantation has been developed. It includes a full nutritional and functional assessment of patients and offers enhanced dietetic, physiotherapeutic, and psychosocial care. For inflammatory bowel diseases, two new drugs have emerged: risankizumab for Crohn's disease and upadacitinib for ulcerative colitis. Their benefits and significance relative to existing treatments are presented. Finally, a standardized nomenclature for steatotic liver disease (SLD) has been published and accepted by the scientific communities. The two main SLDs are alcohol-related liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD). Patients suffering from both diseases are classified as MetALD. This article reviews the diagnostic criteria for these common conditions.
- Affiliations
Citations
Dahlqvist, G., Dewit, O., Lanthier, N., & Starkel, P. (2024). Transplantation, MICI et stéatose hépatique : quelques nouveautés en 2023. Louvain médical, 143(02-03), 183-188. https://hdl.handle.net/2078.5/240432 (Original work published 2024)